Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer
The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care. All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Canc...
Gespeichert in:
| Veröffentlicht in: | HPB (Oxford, England) England), 2023-10, Vol.25 (10), p.1195-1202 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1202 |
|---|---|
| container_issue | 10 |
| container_start_page | 1195 |
| container_title | HPB (Oxford, England) |
| container_volume | 25 |
| creator | Graus, Merlijn U.J.E. de Hingh, Ignace H.J.T. Besselink, Marc G. Bruno, Marco J. Wilmink, Johanna W. de Meijer, Vincent E. van Velthuysen, Marie-Louise F. Valkenburg-van Iersel, Liselot B.J. van der Geest, Lydia G.M. de Vos-Geelen, Judith Siesling, S. van Hoeve, J.C. Merkx, M.A.W. de Wit, N.J. Helsper, C.W. Dingemans, I. Nagtegaal, I.D. van der Schaaf, M. van Gils, C.H. van Weert, H.C.P.M. Verheij, M. |
| description | The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care.
All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017–2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan–Meier and Log-rank tests.
In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017–2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017–2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065).
This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer. |
| doi_str_mv | 10.1016/j.hpb.2023.04.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10162845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1365182X2300134X</els_id><sourcerecordid>2820023034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-74c6fb424a38920eef429c7b371838961f7244edcc5506feba0d994e53a7ef413</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS0EoqXwA9ggL1k0wa_EiVggdHlVqlQWgNhZjjPh-iqJg-1cxL9nwi0VbFh57PnmeHQOIU85Kznj9YtDuV-6UjAhS6ZKxvU9cs6V1oWotLqPtayrgjfi6xl5lNKBMYFj7UNyJrWQdSP5ORk_hmUdbfZhLjqboKd-WqzLNAx0d_Pl6k3BWxpm6mfne5gdXNIcweYJ5nxJ7dzTtMajP9pxm1hQCBuJ_vB5j7fZbax31GEJ8TF5MNgxwZPb84J8fvf20-5DcX3z_mr3-rpwqhK50MrVQ6eEsrJpBQMYlGid7qTmDb7UfNBCKeidqypWD9BZ1retgkpajSyXF-TVSXdZuwk5XCna0SzRTzb-NMF6829n9nvzLRzN5qpoVIUKz28VYvi-Qspm8snBONoZwpqMaAS6KZlUiPIT6mJIKcJw9w9nvwXNwWBMZovJMGUwJpx59veCdxN_ckHg5QkAtOnoIZrk_GZ_7yO4bPrg_yP_C_I3pBg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820023034</pqid></control><display><type>article</type><title>Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Graus, Merlijn U.J.E. ; de Hingh, Ignace H.J.T. ; Besselink, Marc G. ; Bruno, Marco J. ; Wilmink, Johanna W. ; de Meijer, Vincent E. ; van Velthuysen, Marie-Louise F. ; Valkenburg-van Iersel, Liselot B.J. ; van der Geest, Lydia G.M. ; de Vos-Geelen, Judith ; Siesling, S. ; van Hoeve, J.C. ; Merkx, M.A.W. ; de Wit, N.J. ; Helsper, C.W. ; Dingemans, I. ; Nagtegaal, I.D. ; van der Schaaf, M. ; van Gils, C.H. ; van Weert, H.C.P.M. ; Verheij, M.</creator><creatorcontrib>Graus, Merlijn U.J.E. ; de Hingh, Ignace H.J.T. ; Besselink, Marc G. ; Bruno, Marco J. ; Wilmink, Johanna W. ; de Meijer, Vincent E. ; van Velthuysen, Marie-Louise F. ; Valkenburg-van Iersel, Liselot B.J. ; van der Geest, Lydia G.M. ; de Vos-Geelen, Judith ; Siesling, S. ; van Hoeve, J.C. ; Merkx, M.A.W. ; de Wit, N.J. ; Helsper, C.W. ; Dingemans, I. ; Nagtegaal, I.D. ; van der Schaaf, M. ; van Gils, C.H. ; van Weert, H.C.P.M. ; Verheij, M. ; for the Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium ; SONCOS (Dutch Multidisciplinary Oncology Foundation) ; Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA) ; Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</creatorcontrib><description>The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care.
All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017–2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan–Meier and Log-rank tests.
In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017–2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017–2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065).
This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer.</description><identifier>ISSN: 1365-182X</identifier><identifier>EISSN: 1477-2574</identifier><identifier>DOI: 10.1016/j.hpb.2023.04.017</identifier><identifier>PMID: 37236831</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>COVID-19 - epidemiology ; COVID-19 - therapy ; Humans ; Incidence ; Original ; Pancreatic Neoplasms ; Pancreatic Neoplasms - epidemiology ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Pandemics ; Survival Rate</subject><ispartof>HPB (Oxford, England), 2023-10, Vol.25 (10), p.1195-1202</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2023 The Authors. Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-74c6fb424a38920eef429c7b371838961f7244edcc5506feba0d994e53a7ef413</citedby><cites>FETCH-LOGICAL-c452t-74c6fb424a38920eef429c7b371838961f7244edcc5506feba0d994e53a7ef413</cites><orcidid>0000-0002-7900-5917 ; 0000-0003-0435-9494 ; 0000-0002-3645-1458 ; 0000-0003-2578-1766 ; 0000-0001-6686-2904 ; 0000-0003-2650-9350 ; 0000-0003-2925-9908</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162845/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162845/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37236831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Graus, Merlijn U.J.E.</creatorcontrib><creatorcontrib>de Hingh, Ignace H.J.T.</creatorcontrib><creatorcontrib>Besselink, Marc G.</creatorcontrib><creatorcontrib>Bruno, Marco J.</creatorcontrib><creatorcontrib>Wilmink, Johanna W.</creatorcontrib><creatorcontrib>de Meijer, Vincent E.</creatorcontrib><creatorcontrib>van Velthuysen, Marie-Louise F.</creatorcontrib><creatorcontrib>Valkenburg-van Iersel, Liselot B.J.</creatorcontrib><creatorcontrib>van der Geest, Lydia G.M.</creatorcontrib><creatorcontrib>de Vos-Geelen, Judith</creatorcontrib><creatorcontrib>Siesling, S.</creatorcontrib><creatorcontrib>van Hoeve, J.C.</creatorcontrib><creatorcontrib>Merkx, M.A.W.</creatorcontrib><creatorcontrib>de Wit, N.J.</creatorcontrib><creatorcontrib>Helsper, C.W.</creatorcontrib><creatorcontrib>Dingemans, I.</creatorcontrib><creatorcontrib>Nagtegaal, I.D.</creatorcontrib><creatorcontrib>van der Schaaf, M.</creatorcontrib><creatorcontrib>van Gils, C.H.</creatorcontrib><creatorcontrib>van Weert, H.C.P.M.</creatorcontrib><creatorcontrib>Verheij, M.</creatorcontrib><creatorcontrib>for the Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</creatorcontrib><creatorcontrib>SONCOS (Dutch Multidisciplinary Oncology Foundation)</creatorcontrib><creatorcontrib>Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA)</creatorcontrib><creatorcontrib>Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</creatorcontrib><title>Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer</title><title>HPB (Oxford, England)</title><addtitle>HPB (Oxford)</addtitle><description>The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care.
All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017–2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan–Meier and Log-rank tests.
In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017–2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017–2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065).
This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer.</description><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Original</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - epidemiology</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Pandemics</subject><subject>Survival Rate</subject><issn>1365-182X</issn><issn>1477-2574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1TAQhS0EoqXwA9ggL1k0wa_EiVggdHlVqlQWgNhZjjPh-iqJg-1cxL9nwi0VbFh57PnmeHQOIU85Kznj9YtDuV-6UjAhS6ZKxvU9cs6V1oWotLqPtayrgjfi6xl5lNKBMYFj7UNyJrWQdSP5ORk_hmUdbfZhLjqboKd-WqzLNAx0d_Pl6k3BWxpm6mfne5gdXNIcweYJ5nxJ7dzTtMajP9pxm1hQCBuJ_vB5j7fZbax31GEJ8TF5MNgxwZPb84J8fvf20-5DcX3z_mr3-rpwqhK50MrVQ6eEsrJpBQMYlGid7qTmDb7UfNBCKeidqypWD9BZ1retgkpajSyXF-TVSXdZuwk5XCna0SzRTzb-NMF6829n9nvzLRzN5qpoVIUKz28VYvi-Qspm8snBONoZwpqMaAS6KZlUiPIT6mJIKcJw9w9nvwXNwWBMZovJMGUwJpx59veCdxN_ckHg5QkAtOnoIZrk_GZ_7yO4bPrg_yP_C_I3pBg</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Graus, Merlijn U.J.E.</creator><creator>de Hingh, Ignace H.J.T.</creator><creator>Besselink, Marc G.</creator><creator>Bruno, Marco J.</creator><creator>Wilmink, Johanna W.</creator><creator>de Meijer, Vincent E.</creator><creator>van Velthuysen, Marie-Louise F.</creator><creator>Valkenburg-van Iersel, Liselot B.J.</creator><creator>van der Geest, Lydia G.M.</creator><creator>de Vos-Geelen, Judith</creator><creator>Siesling, S.</creator><creator>van Hoeve, J.C.</creator><creator>Merkx, M.A.W.</creator><creator>de Wit, N.J.</creator><creator>Helsper, C.W.</creator><creator>Dingemans, I.</creator><creator>Nagtegaal, I.D.</creator><creator>van der Schaaf, M.</creator><creator>van Gils, C.H.</creator><creator>van Weert, H.C.P.M.</creator><creator>Verheij, M.</creator><general>Elsevier Ltd</general><general>The Authors. Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7900-5917</orcidid><orcidid>https://orcid.org/0000-0003-0435-9494</orcidid><orcidid>https://orcid.org/0000-0002-3645-1458</orcidid><orcidid>https://orcid.org/0000-0003-2578-1766</orcidid><orcidid>https://orcid.org/0000-0001-6686-2904</orcidid><orcidid>https://orcid.org/0000-0003-2650-9350</orcidid><orcidid>https://orcid.org/0000-0003-2925-9908</orcidid></search><sort><creationdate>20231001</creationdate><title>Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer</title><author>Graus, Merlijn U.J.E. ; de Hingh, Ignace H.J.T. ; Besselink, Marc G. ; Bruno, Marco J. ; Wilmink, Johanna W. ; de Meijer, Vincent E. ; van Velthuysen, Marie-Louise F. ; Valkenburg-van Iersel, Liselot B.J. ; van der Geest, Lydia G.M. ; de Vos-Geelen, Judith ; Siesling, S. ; van Hoeve, J.C. ; Merkx, M.A.W. ; de Wit, N.J. ; Helsper, C.W. ; Dingemans, I. ; Nagtegaal, I.D. ; van der Schaaf, M. ; van Gils, C.H. ; van Weert, H.C.P.M. ; Verheij, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-74c6fb424a38920eef429c7b371838961f7244edcc5506feba0d994e53a7ef413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Original</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - epidemiology</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Pandemics</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Graus, Merlijn U.J.E.</creatorcontrib><creatorcontrib>de Hingh, Ignace H.J.T.</creatorcontrib><creatorcontrib>Besselink, Marc G.</creatorcontrib><creatorcontrib>Bruno, Marco J.</creatorcontrib><creatorcontrib>Wilmink, Johanna W.</creatorcontrib><creatorcontrib>de Meijer, Vincent E.</creatorcontrib><creatorcontrib>van Velthuysen, Marie-Louise F.</creatorcontrib><creatorcontrib>Valkenburg-van Iersel, Liselot B.J.</creatorcontrib><creatorcontrib>van der Geest, Lydia G.M.</creatorcontrib><creatorcontrib>de Vos-Geelen, Judith</creatorcontrib><creatorcontrib>Siesling, S.</creatorcontrib><creatorcontrib>van Hoeve, J.C.</creatorcontrib><creatorcontrib>Merkx, M.A.W.</creatorcontrib><creatorcontrib>de Wit, N.J.</creatorcontrib><creatorcontrib>Helsper, C.W.</creatorcontrib><creatorcontrib>Dingemans, I.</creatorcontrib><creatorcontrib>Nagtegaal, I.D.</creatorcontrib><creatorcontrib>van der Schaaf, M.</creatorcontrib><creatorcontrib>van Gils, C.H.</creatorcontrib><creatorcontrib>van Weert, H.C.P.M.</creatorcontrib><creatorcontrib>Verheij, M.</creatorcontrib><creatorcontrib>for the Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</creatorcontrib><creatorcontrib>SONCOS (Dutch Multidisciplinary Oncology Foundation)</creatorcontrib><creatorcontrib>Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA)</creatorcontrib><creatorcontrib>Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>HPB (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Graus, Merlijn U.J.E.</au><au>de Hingh, Ignace H.J.T.</au><au>Besselink, Marc G.</au><au>Bruno, Marco J.</au><au>Wilmink, Johanna W.</au><au>de Meijer, Vincent E.</au><au>van Velthuysen, Marie-Louise F.</au><au>Valkenburg-van Iersel, Liselot B.J.</au><au>van der Geest, Lydia G.M.</au><au>de Vos-Geelen, Judith</au><au>Siesling, S.</au><au>van Hoeve, J.C.</au><au>Merkx, M.A.W.</au><au>de Wit, N.J.</au><au>Helsper, C.W.</au><au>Dingemans, I.</au><au>Nagtegaal, I.D.</au><au>van der Schaaf, M.</au><au>van Gils, C.H.</au><au>van Weert, H.C.P.M.</au><au>Verheij, M.</au><aucorp>for the Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</aucorp><aucorp>SONCOS (Dutch Multidisciplinary Oncology Foundation)</aucorp><aucorp>Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA)</aucorp><aucorp>Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer</atitle><jtitle>HPB (Oxford, England)</jtitle><addtitle>HPB (Oxford)</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>25</volume><issue>10</issue><spage>1195</spage><epage>1202</epage><pages>1195-1202</pages><issn>1365-182X</issn><eissn>1477-2574</eissn><abstract>The COVID-19 pandemic has put substantial strain on the healthcare system of which the effects are only partly elucidated. This study aimed to investigate the impact on pancreatic cancer care.
All patients diagnosed with pancreatic cancer between 2017 and 2020 were selected from the Netherlands Cancer Registry. Patients diagnosed and/or treated in 2020 were compared to 2017–2019. Monthly incidence was calculated. Patient, tumor and treatment characteristics were analyzed and compared using Chi-squared tests. Survival data was analyzed using Kaplan–Meier and Log-rank tests.
In total, 11019 patients were assessed. The incidence in quarter (Q)2 of 2020 was comparable with that in Q2 of 2017–2019 (p = 0.804). However, the incidence increased in Q4 of 2020 (p = 0.031), mainly due to a higher incidence of metastatic disease (p = 0.010). Baseline characteristics, surgical resection (15% vs 16%; p = 0.466) and palliative systemic therapy rates (23% vs 24%; p = 0.183) were comparable. In 2020, more surgically treated patients received (neo)adjuvant treatment compared to 2017–2019 (73% vs 67%; p = 0.041). Median overall survival was comparable (3.8 vs 3.8 months; p = 0.065).
This nationwide study found a minor impact of the COVID-19 pandemic on pancreatic cancer care and outcome. The Dutch health care system was apparently able to maintain essential care for patients with pancreatic cancer.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37236831</pmid><doi>10.1016/j.hpb.2023.04.017</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7900-5917</orcidid><orcidid>https://orcid.org/0000-0003-0435-9494</orcidid><orcidid>https://orcid.org/0000-0002-3645-1458</orcidid><orcidid>https://orcid.org/0000-0003-2578-1766</orcidid><orcidid>https://orcid.org/0000-0001-6686-2904</orcidid><orcidid>https://orcid.org/0000-0003-2650-9350</orcidid><orcidid>https://orcid.org/0000-0003-2925-9908</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-182X |
| ispartof | HPB (Oxford, England), 2023-10, Vol.25 (10), p.1195-1202 |
| issn | 1365-182X 1477-2574 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10162845 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | COVID-19 - epidemiology COVID-19 - therapy Humans Incidence Original Pancreatic Neoplasms Pancreatic Neoplasms - epidemiology Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Pandemics Survival Rate |
| title | Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A33%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Population-based%20impact%20of%20COVID-19%20on%20incidence,%20treatment,%20and%20survival%20of%20patients%20with%20pancreatic%20cancer&rft.jtitle=HPB%20(Oxford,%20England)&rft.au=Graus,%20Merlijn%20U.J.E.&rft.aucorp=for%20the%20Dutch%20Pancreatic%20Cancer%20Group%20(DPCG)%20and%20the%20COVID%20&%20Cancer-NL%20consortium&rft.date=2023-10-01&rft.volume=25&rft.issue=10&rft.spage=1195&rft.epage=1202&rft.pages=1195-1202&rft.issn=1365-182X&rft.eissn=1477-2574&rft_id=info:doi/10.1016/j.hpb.2023.04.017&rft_dat=%3Cproquest_pubme%3E2820023034%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2820023034&rft_id=info:pmid/37236831&rft_els_id=S1365182X2300134X&rfr_iscdi=true |